BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, January 23, 2026
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Financings for Nov. 15, 2022

Nov. 15, 2022
Biopharmas raising money in public or private financings, including: Bonum, Casma, Clearmind.
Read More
International currency symbols

Gap closes with last year as med-tech financings collect $35.7 billion

Nov. 14, 2022
By Karen Carey
A large notes offering this month and a pick-up in public raises have boosted med-tech financings, which are now tracking similarly with 2019. So far this year, the med-tech industry has raised $35.7 billion through 457 transactions. The amount raised is down by 23% in comparison with the same time frame in 2021, although a few months ago that gap was 48%. The current volume is down by 25.4%.
Read More
Hand holding dollar sign

Osler raises $85M as it embarks on bid for regulator approvals

Nov. 14, 2022
By Nuala Moran
Osler Diagnostics Ltd. has raised $85 million in a series C round, as it embarks on clinical testing to secure regulatory approvals for its portable central lab quality diagnostics system.
Read More
Coin stacks, dollar signs and up arrow

Zenas nets $118M in series B round to support phase III trial of obexelimab

Nov. 14, 2022
By Doris Yu
Zenas Biopharma LLC has raised $118 million in a series B round to support a global phase III trial of its lead asset as well as other immunotherapies for autoimmune diseases in its pipeline. The study, expected to begin in 2023, will evaluate obexelimab for the treatment of patients with immunoglobulin G4-related disease in late 2022.
Read More

Financings for Nov. 14, 2022

Nov. 14, 2022
Biopharmas raising money in public or private financings, including: Cue, MBX, Renibus, Taurx.
Read More

Financings for Nov. 11, 2022

Nov. 11, 2022
Biopharmas raising money in public or private financings, including: Athersys, Avicenna, Lipidio .
Read More
Coins and seedling

Easy-Flow completes angel round to develop peripheral intervention products

Nov. 10, 2022
By Doris Yu
Shanghai Easy-Flow Medical Technology Co. Ltd. has completed an angel round to develop its peripheral intervention products. The round, which the company claims to be in the “tens of millions of yuan,” was led by Legend Capital.
Read More

Financings for Nov. 10, 2022

Nov. 10, 2022
Med-tech firms raising money in public or private financings, including: Debiopharm, GE Healthcare, PureFDA Medical Technology, Yonalink.
Read More

Financings for Nov. 10, 2022

Nov. 10, 2022
Biopharmas raising money in public or private financings, including: Alzecure, Avstera, Biovaxys, Lipidio, Psyence, Rallybio.
Read More
Cancer

Avstera to use funding to advance cancer programs for solid tumors

Nov. 10, 2022
Avstera Therapeutics Corp. has completed a seed round of US$4.55 million to advance its lead cancer programs targeting solid tumors.
Read More
Previous 1 2 … 303 304 305 306 307 308 309 310 311 … 647 648 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 22, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 22, 2026.
  • Illustration of human body surrounded by DNA, cell and drug icons

    Cell/gene therapy sector now sustainable; China competition mounting

    BioWorld
    There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
  • Illustration of magnifying glass inspecting brain

    Neurotrimin unveiled as marker in intellectual disability

    BioWorld Science
    Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
  • Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

    BioWorld
    With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing